Anticoagulant Effect at the Time of Epidural Catheter Removal in Patients Receiving Twice-daily or Once-daily Low-molecular-weight Heparin and Continuous Epidural Analgesia after Orthopedic Surgery

Summary

In patients who receive co-administered low-molecular-weight heparin (LMWH) and continuous epidural analgesia (CEA) after orthopedic surgery, there is concern about an increased risk of a spinal epidural hematoma. The practice of twice-daily LMWH dosing in North America might, in part, account for the greater number of epidural hematomas reports compared to Europe where once-daily LMWH is used. We performed a prospective cohort study in patients who had orthopedic surgery and received co-administered LMWH and CEA. We investigated the trough anticoagulant effect, as measured by an anti-Xa heparin level, at the time of epidural catheter removal in patients who received twice-daily or once-daily LMWH. Twenty-five patients who received enoxaparin, 30 mg twice-daily, and 25 patients who received dalteparin, 5,000 IU once-daily, had anti-Xa heparin levels measured on the second or third post-operative day at the time of epidural catheter removal. In patients who received twice-daily enoxaparin, or once-daily dalteparin, the anti-Xa heparin level was measured, on average, 10.4 h and 21.8 h, respectively, after the preceding LWMH dose. All 25 patients who received once-daily LMWH had an anti-Xa heparin level <0.10 U/ml at the time of catheter removal. Of 25 patients who received twice-daily LMWH, the anti-Xa heparin level at the time of catheter removal was >0.20 U/ml in 5 patients (P = 0.050), and >0.10 U/ml in 7 patients (P = 0.009). We conclude that in patients who are receiving co-administered LMWH and CEA after orthopedic surgery, twice-daily but not once-daily LMWH administration is more likely to be associated with a clinically important anticoagulant effect at the time of epidural catheter removal.

Keywords

Low-molecular-weight heparin - epidural analgesia - bleeding - thrombosis

• References

• 1 Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinalepidural anesthesia. Anesth Analg 1994; 79: 1165-77.
• 2 Horlocker TT, Heit JA. Low molecular weight heparin: Biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines or regional anesthetic management. Anesth Analg 1997; 85: 874-85.
• 3 Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson Jr FA. et al. Prevention of venous thromboembolism. Chest 2001; 119: S132-75.
• 4 Singelyn FJ, Deyaert M, Joris D, Pendeville E, Gouverneur JM. Effects of intravenous patient-controlled analgesia with morphine, continuous epidural analgesia, and continuous three-in-one-block on postoperative pain and knee rehabilitation after unilateral total knee arthroplasty. Anesth Analg 1998; 87: 88-92.
• 5 Lumpkin MM. FDA Public Health Advisory: Reports of epidural or spinal hematomas with the concurrent use of low molecular weight heparin and spinal/epidural anesthesia or spinal puncture. Anesthesiology 1999; 88: 27A-28A.
• 6 Horlocker TT, Wedel DJ. Neuraxial block and low-molecular-weight heparin: balancing perioperative prophylaxis regimens, and guidelines for regional anesthetic management. Reg Anesth Pain Med 1998; 23: 164-77.
• 7 Tryba M, Wedel DJ. Central neuraxial block and low molecular weight heparin (enoxaparin): Lessons learned from two different dosage regimens in two continents. Acta Anaesthesiol Scand 1997; 41 (Suppl. 111) 100-4.
• 8 Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989; 62: 940-4.
• 9 Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses 20 to 80 mg. J Clin Pharmacol 1988; 28: 609-18.
• 10 Mismetti P, Laporte-Simitsidis S, Navarro C, Sie P, d’Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and antithrombin activities of a low-molecular weight heparin (nadroparin). Thromb Haemost 1998; 79: 1162-5.
• 11 Collignon F, Frydman C, Caplain H. et al. Comparison of the pharmacokinetic profiles of three low molecular weight heparins – dalteparin, enoxaparin, nadroparin – administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995; 73: 630-40.
• 12 Eriksson BI, Soderberg K, Widlund L. et al. A comparative study of three low-molecular-weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995; 73: 398-401.
• 13 Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, safety. Chest 2001; 119: 64S-94S.
• 14 Horlocker TT. Low molecular weight heparin and neuraxial anesthesia. Thromb Res 2001; 101: V141-54.
• 15 Schroeder DR. Statistics: detecting a rare adverse drug reaction using spontaneous reports. Reg Anesth Pain Med 1998; 23 (Suppl. 02) 183-9.
• 16 Lawton MT, Porter RW, Heiserman JE, Jacobowitz R, Sonntag VKH, Dickman CA. Surgical management of spinal epidural hematoma: relationship between surgical timing and neurological outcome. J Neurosurg 1995; 83: 1-7.
• 17 Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE. et al. Timing of initial administration of low-molecular weight heparin prophylaxis against deep vein thrombosis in patients following hip arthroplasty. Arch Intern Med 2001; 161: 1952-60.
• 18 Capdevilla X, Barthelet Y, Biboulet P, Ryckwaert Y, Rubenovitch J, d’Athis F. Effects of peropoperative analgesic technique on the surgical outcome and duration of rehabilitation after major knee surgery. Anesthesiology 1999; 91: 8-15.
• 19 Schwander D, Bachmann F. Herparine et anesthesies medullaires: analyse de decision. Ann Fr Anesth Reanim 1991; 10: 284-96.
• 20 Tryba M. Ruckmarksnahe regionalanasthesie und niedermolekulare heparine. Pro Anasth Intensivmed Notfallmed Schmerzther 1993; 28: 179-81.
• 21 Cockroft DW, Gault MN. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.